Abstract Review Categories

100s - Red Cell Physiology and Disorders

Categories 101–114 exclude studies of transplantation or gene therapy for red cell disorders and anemias which should be submitted to 700s or 801.

101. Red Cells and Erythropoiesis, Excluding Iron

Basic, translational, clinical, and epidemiological studies of erythropoiesis and normal or abnormal RBC structure and function. Includes anemias related to red cell underproduction, overproduction (other than myeloproliferative disorders, see 600s), autoimmune destruction, nutritional deficiencies excluding iron (see 102), infections of erythroid cells (eg malaria), and systemic diseases, inflammation, and aging, other than disorders linked to perturbed iron metabolism (see 102) or clonal hematopoiesis (see 503). For anemias related to paroxysmal nocturnal hemoglobinuria, Diamond-Blackfan anemia, or other acquired or inherited bone marrow failure syndromes, see 508 or 509. For health services and outcomes research see 901 or 904.

102. Iron Homeostasis and Biology

Basic, translational, clinical, and epidemiological studies of iron homeostasis and acquired or congenital disorders resulting in iron overload, iron deficiency or heme pathway dysfunction (porphyrias). Also includes abnormalities of iron homeostasis in the context of inflammation or aging. Iron dysregulation studies studied specifically in the context of thalassemia see 112. For health services and outcomes research see 901 or 904.

112. Thalassemia and Globin Gene Regulation

Basic, translational, clinical, and epidemiological studies of thalassemias, and investigation of mechanisms controlling hemoglobin production. Encompasses risk factors, diagnosis, complications, drug treatments, pharmacologic interactions, and disease course. Studies of iron dynamics in the context of thalassemia are appropriate. Studies of thalassemic hemoglobin disorders such as sickle thalassemia see 113 or 114. Gene therapy and transplantation studies see 801 or 700s. For health services and outcomes research see 901 and 904.

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational

Basic and translational studies of sickle cell disease, sickle cell trait, sickle thalassemia, and other hemoglobinopathies.

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

Clinical and epidemiological studies of sickle cell disease, sickle cell trait, sickle thalassemia and other hemoglobinopathies. Encompasses risk factors, diagnosis, complications, drug treatments, pharmacologic interactions, and disease course. Gene therapy and transplantation studies see 700s or 801. For health services and outcomes research see 901 or 904.

200s - Leukocytes, Inflammation and Immunology

These categories generally exclude hematopoiesis (500s), leukemias (600s), or aspects of leukocyte biology related to transplantation, cell processing or gene therapies (700s and 801).

201. Granulocytes, Monocytes and Macrophages

Basic, translational, clinical, and epidemiological studies of normal or abnormal neutrophils, monocytes, dendritic cells, histiocytes, eosinophils, basophils, or mast cells, including acquired or congenital disorders of the production, function, or trafficking of these cells, including hematologic hyperinflammatory syndromes (HLH, MAS etc) and WHIM, excluding MDS, MPD and AML (see 600s). Treatment of neutropenia or other myeloid cellular deficiencies with cytokines or other drugs are appropriate, including applications in non-hematologic diseases, but those focused on treatment of cytopenias resulting from hematologic malignancies or their treatment would be better suited to 600s or 700s. Abstracts focused on neutropenia in the context of bone marrow failure or cancer predisposition syndromes see 508 or 509. For health services and outcomes research see 901 or 904.

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

Basic, translational, clinical, and epidemiological studies of the development and function of B cells, T cells, natural killer cells, or other lymphoid lineages, including acquired or congenital immunodeficiencies and immune dysregulation disorders. Studies in the context of infections (including COVID-19), immunotherapies, or other environmental challenges are appropriate, as well as investigations of interleukins, interferons, or factors which modulate immune cell function. Excludes pre-malignant and malignant lymphocyte and plasma cell disorders (see 600s). Clinical and manufacturing/engineering studies of lymphoid cells for adoptive transfer see 704 or 711. For health services and outcomes research see 901 and 904.

300s - Hemostasis, Thrombosis and Vascular Wall Biology

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational

Basic and translational studies of vascular and endothelial cell biology, angiogenesis, thrombosis, thrombotic microangiopathies/thrombocytopenias (TTP/HUS, HIT, HELLP, VITT, COVID-19 thrombosis, antiphospholipid syndromes and related disorders), and all aspects of platelet biology and function, including von Willebrand factor-platelet interactions. May include development of diagnostic assays or laboratory tests for platelet or thrombotic disorders. Studies of hematopoiesis focused on megakaryocytopoiesis may be better suited to 501. Basic/translational studies of coagulation and fibrinolysis see 321.

311. Disorders of Platelet Number or Function: Clinical and Epidemiological

Clinical and epidemiological studies of thrombocytopenia, including autoimmune, alloimmune, infectious and drug-related disorders; as well as intrinsic and secondary abnormalities of platelet function. Encompasses risk factors, diagnosis, complications, treatments, and disease course. Clinical studies of thrombotic microangiopathies/thrombocytopenias (TTP/HUS, HIT, VITT, anti-phospholipid syndromes, COVID-19 or vaccine related) belong in 331. Abnormalities in platelet counts or function related to myeloproliferative disorders or other hematologic malignancies belong in 600s. For health services and outcomes research see 901 or 904.

321. Coagulation and Fibrinolysis: Basic and Translational

Basic or translational studies of clotting factors, fibrinolytic proteins, and related molecules which take part in blood coagulation or fibrinolysis, as well as enzymes or proteases involved in their synthesis or degradation. Interactions of vWF with platelets/endothelium may be better suited to 301. May include development of diagnostic assays or laboratory tests for coagulopathies.

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological

Clinical and epidemiological studies of congenital and acquired disorders of coagulation, fibrinolysis, von Willebrand’s disease, or other bleeding diatheses. Encompasses risk factors, diagnosis, complications, drug treatments, pharmacologic interactions, and disease course. Excludes studies of abnormal bleeding due to thrombocytopenia or platelet dysfunction (see 311). Studies of the processing of fractionated blood or plasma components used to treat coagulation disorders see 401. Gene therapies for these disorders see 801. For health services and outcomes research see 901 or 904.

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, outcomes, complications, prognosis, and treatment of thrombotic microangiopathies/thrombocytopenias, including TTP/HUS, HIT, antiphospholipid syndromes, HELLP, thromboses associated with COVID-19 disease, SARS-CoV-2 vaccine-induced thrombotic thrombocytopenia (VITT), and other related acquired and inherited disorders. For health services and outcomes research see 901 or 904.

332. Thrombosis and Anticoagulation: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, complications, prognosis, and treatment of thromboembolism and inherited and acquired hypercoagulability states. May also include design and testing of assays for monitoring of anticoagulant and antithrombotic therapies. Studies focused on thrombotic microangiopathies/thrombocytopenias (eg TTP/HUS, HIT, antiphospholipid syndromes, HELLP) and on COVID-19 related thrombosis or vaccine-induced thrombotic thrombocytopenia (VITT) see 331. For health services and outcomes research see 901 or 904.

400s - Transfusion Medicine

401. Blood Transfusion

Basic, translational, clinical, and epidemiological studies of collection, handling, storage, modification, or administration of blood or blood components. Also includes RBC or platelet antigen and antibody testing, prevention/detection/treatment of blood-borne infections, and complications of transfusions. Cell processing for transplantation or adoptive cell therapies see 704 and 711. For health services and outcomes research see 901 or 904.

500s - Hematopoiesis

Abstracts submitted to 501–506 should have as their primary focus cellular and molecular events related to normal, aged or developing or regenerating hematopoiesis. Studies focused on neoplastic transformation should be submitted to 600s. Studies focused solely on erythropoiesis should be submitted to 101.

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational

Basic and translational studies of the cellular and molecular biology of hematopoietic stem and progenitor cells (HSPCs), including during development. Studies focused on differentiation of HSPCs from pluripotent stem cells are also appropriate. Studies of cytokines and cytokine receptors or other molecules controlling hematopoiesis are appropriate. Excludes studies of HSPC mobilization and engraftment (see 701), clinical collection and processing of HSPCs (see 711) or the interaction of microenvironmental cells with HSPCs (see 506). Studies focused solely on erythropoiesis should be submitted to 101.

503. Clonal Hematopoiesis, Aging and Inflammation

Basic, translational, clinical and epidemiological studies investigating mechanisms (including inflammation), risk factors, complications, prognosis, and outcomes related to acquired somatic clonal mutations and/or aging of hematopoietic stem and progenitor cells. Studies focused solely on anemias of inflammation or aging should be submitted to 101 or 102. VEXAS would also be appropriate for this category. Studies focused on the impact of the bone marrow microenvironment should be submitted to 506. For health services and outcomes research see 901 or 904.

506. Bone Marrow Microenvironment

Basic, translational, clinical, and epidemiological studies of the bone marrow hematopoietic microenvironment, including studies focused on cellular or matrix component(s) or factor(s) secreted from cellular components participating in the modulation of hematopoiesis and influencing either normal, pre-leukemic or leukemic stem cells. Includes studies of mesenchymal stromal cells or other microenvironmental cells in vitro and in animal models, as well as clinical trials involving transplantation of these cells for hematopoietic support or immune modulation.

508. Bone Marrow Failure: Acquired

Basic, translational, clinical, and epidemiological studies of acquired bone marrow failure, including aplastic anemia, hypo-productive cytopenias, paroxysmal nocturnal hemoglobinuria, and VEXAS. For inherited bone marrow failure and/or cancer predisposition syndromes see 509. For health services and outcomes research see 901 or 904.

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

Basic, translational, clinical, and epidemiological studies of congenital/inherited bone marrow failure and blood cancer predisposition syndromes, eg Fanconi anemia, Diamond-Blackfan anemia, telomeropathies, Shwachman-Diamond syndrome, GATA2 deficiency, RUNX1 deficiency, DDX4-related syndromes, and any other germline bone marrow failure or blood cancer predisposition syndromes. For health services and outcomes research, see 901 or 904.

600s - Hematologic Malignancy

These categories exclude studies of normal hematopoietic cells (instead see 500s), unless directly linked to oncogenesis. Studies of transplantation or cellular immunotherapies in hematologic malignancies, including comparisons to drug therapies, see 700s. Health services and outcomes research focusing on hematologic malignancies see 900s.

602. Myeloid Oncogenesis: Basic

Basic and mechanistic studies of gene expression, epigenetics, DNA repair, metabolism and/or other cellular functions disrupted in myeloid or non-lineage specific oncogenesis. Translational studies focused on specific malignancies and/or samples from patients with these malignancies may be more appropriate for other 600s categories (see below).

603. Lymphoid Oncogenesis: Basic

Basic and mechanistic studies of gene expression, epigenetics, DNA repair, metabolism and/or other cellular functions disrupted in lymphoid oncogenesis. Translational studies focused on specific malignancies and/or on samples from patients with these malignancies may be more appropriate for other 600s categories (see below).

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms

Basic, translational, preclinical animal model, and very early phase clinical studies of the development and interactions of non-cellular therapeutic agents and their receptors, binding sites or ligands as related to myeloid neoplasms. Includes studies of pharmacokinetics, drug transport, metabolism, drug activity, and drug resistance. Discovery and screening studies of small molecule inhibitors and approaches involving chemical biology may be more appropriate for 802.

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms

Basic, translational, preclinical animal model, and very early phase clinical studies of the development and interactions of non-cellular therapeutic agents and their receptors, binding sites or ligands as related to lymphoid neoplasms. Includes studies of pharmacokinetics, drug transport, metabolism, drug activity, and drug resistance. Discovery and screening studies of small molecule inhibitors and approaches involving chemical biology may be more appropriate for 802.

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological

Clinical and epidemiological studies of acute lymphocytic leukemias, including risks factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes such as quality of life. Translational biomarker, “omics” or minimal residual disease studies may be more appropriate for 618. For health services and outcomes research related see 902 or 905.

613. Acute Myeloid Leukemias: Clinical and Epidemiological

Clinical and epidemiological studies of acute myeloid leukemias, including risks factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes such as quality-of-life. Translational biomarker, “omics” or minimal residual disease studies may be more appropriate for 617. For health services and outcomes research see 903 or 906.

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies

Clinical studies of drug therapies, biological agents, and non-cellular immunotherapies. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular immunotherapies see 700s. Includes studies of disease response, complications, survival, quality of life and other parameters related to treatment. For health services and outcomes research see 902 or 905.

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies

Clinical studies of commercially available drug therapies, biological agents, or non-cellular immunotherapies. Includes studies of disease response, complications, survival, quality of life and other parameters related to treatment. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular immunotherapies, see 700s. For health services and outcomes research see 903 or 906.

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies

Clinical studies of investigational (non-commercially available) drug therapies, biological agents, or non-cellular immunotherapies. Includes studies of disease response, complications, survival, quality of life and other parameters related to treatment. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular immunotherapies, see 700s. For health services and outcomes research see 903 or 906.

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

Translational, epidemiological, and clinical correlation studies of biologic markers and characteristics, such as biochemical, histochemical, metabolic, genetic, karyotypic, or morphologic parameters in the diagnosis and prognosis of AML. May also include minimal residual detection and preclinical or developmental studies of biomarkers intended for eventual application to diagnosis and prognosis. This is the appropriate category for translational research in the molecular “omics” of human AML.

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

Translational, epidemiological, and clinical correlation studies of biologic markers and characteristics, such as biochemical, histochemical, metabolic, genetic, karyotypic, or morphologic parameters in the diagnosis and prognosis of acute lymphoblastic leukemia. May also include minimal residual detection and preclinical or developmental studies of markers intended for eventual application to diagnosis and prognosis. This is the appropriate category for translational research in the molecular “omics” of human ALL.

621. Lymphomas: Translational—Molecular and Genetic

Translational, epidemiological, and clinical correlation studies of genetic, karyotypic, gene expression, and/or epigenetic changes and risk factors in Hodgkin and non-Hodgkin lymphomas, including the development and utilization of preclinical animal models. This is the appropriate category for translational research in the molecular “omics” of lymphomas. May also include minimal residual detection and preclinical or developmental studies of markers intended for clinical and prognostic applications. Basic mechanistic investigations of neoplastic transformation may be better suited for 603, and pharmacologic development and testing of therapeutic agents for 605.

622. Lymphomas: Translational–Non-Genetic

Translational, epidemiological, and clinical correlation studies of Hodgkin and non-Hodgkin lymphomas focused on microenvironment, immune response, metabolic, proteomic, morphologic, cell of origin, or other non-genetic risk factors, including the development and utilization of preclinical animal models. Basic mechanistic investigations of neoplastic transformation may be better suited for 603, and pharmacologic development and testing of therapeutic agents for 605.

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological

Clinical trials, retrospective/observational studies, and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, outcomes, quality of life and treatments (excluding transplantation and cellular immunotherapies) in mantle cell and indolent B cell non-Hodgkin lymphomas; including follicular, Waldenstrom’s, and marginal zone lymphomas, mucosal associated lymphoid tissue, and hairy cell leukemia. Studies including patients with multiple histologies should be submitted to this category if mantle cell or indolent predominate. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular immunotherapies see 700s. For studies of the development and application of biomarkers or “omics” see 621 or 622. For health services or outcomes research see 902 and 905.

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological

Clinical trials, retrospective/observational studies, and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, quality-of-life, outcomes, and treatments (excluding transplantation and cellular immunotherapies) for Hodgkin, T cell and natural killer cell lymphomas; mycosis fungoides, and Sezary syndrome. Studies including patients with multiple histologies should be submitted to this category if Hodgkins or T/NK predominate. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular therapies see 700s. For studies of the development and application of biomarkers or “omics” see 621 or 622. For health services or outcomes research see 902 or 905.

626. Aggressive Lymphomas: Prospective Therapeutic Trials

Clinical trials focused on treatments (excluding transplantation and cellular immunotherapies), complications of treatments, outcomes, and quality-of-life related to treatments for aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas; and post-transplant lymphoproliferative disorders. Studies including patients with multiple histologies should be submitted to this category if aggressive B cell histology predominates. For transplantation and cellular immunotherapies, or comparative trials of treatment regimens versus transplantation or cellular therapies, see 700s. For studies of the development and application of biomarkers or “omics” see 621 or 622. For health services or outcomes research see 902 or 905.

627. Aggressive Lymphomas: Clinical and Epidemiological

Clinical and epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, and long-term outcomes including quality of life in aggressive non-Hodgkin lymphomas; including diffuse large B cell and subtypes, Burkitt, and primary CNS lymphomas; and post-transplant lymphoproliferative disorders. Studies including patients with multiple histologies should be submitted to this category if aggressive B cell histology predominates. For studies of the development and application of biomarkers or “omics” see 621 or 622. For health services or outcomes research see 902 or 905.

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational

Basic and translational studies of chronic myeloid leukemia and myeloproliferative syndromes, including myelofibrosis, essential thrombocythemia, polycythemia vera, clonal mast cell disorders, clonal eosinophilias, and malignant histocytoses. For studies focused on application of molecular diagnostic tools for diagnosis or prognosis see 632 or 634. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited to 602, and pharmacologic development and testing of therapeutic agents for 604.

632. Chronic Myeloid Leukemia: Clinical and Epidemiological

Clinical and epidemiological studies of chronic myeloid leukemia, including risk factors, diagnosis, complications, prognosis, treatments, and long-term outcomes including quality-of-life. For comparative trials of treatment regimens versus transplantation or cellular immunotherapies see 700s. For health services or outcomes research see 903 or 906.

634. Myeloproliferative Syndromes: Clinical and Epidemiological

Clinical and epidemiological studies of myeloproliferative syndromes, including myelofibrosis, essential thrombocythemia, polycythemia vera, mast cell disorders, chronic eosinophilias and malignant histiocytosis. Includes genetic and other risk factors, diagnosis, complications, prognosis, treatment, and long-term outcomes including quality-of-life. For comparative trials of treatment regimens versus transplantation or cellular therapies see 700s. For health services or outcomes research see 903 or 906.

636. Myelodysplastic Syndromes: Basic and Translational

Basic and translational studies of myelodysplastic syndromes, including CMML. For studies focused on the application of molecular diagnostic tools in diagnosis or prognosis see 637. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited to 602, and studies focused on pharmacologic development of therapeutic agents for 604.

637. Myelodysplastic Syndromes – Clinical and Epidemiological

Clinical and epidemiological studies of myelodysplastic syndromes, including RAEB and CMML, encompassing risk factors, diagnosis, complications, prognosis, outcomes, treatments, and long-term outcomes including quality-of-life. For comparative trials of treatment regimens versus transplantation or cellular immuotherapies see 700s. For health services or outcomes research see 903 or 906.

641. Chronic Lymphocytic Leukemias: Basic and Translational

Basic and translational studies of chronic lymphocytic leukemia, including all aspects of disease biology, preclinical model development, and development of diagnostic or prognostic biomarkers including “omics”. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited to 603, and pharmacologic development of new therapeutic agents to 605. For studies on the use of molecular diagnostic tools for diagnosis or prognosis see 642.

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological

Clinical and epidemiological studies focused on risk factors, diagnosis, complications, prognosis, treatments excluding transplantation and cellular immunotherapies, and long-term outcomes including quality-of-life. Includes the use of biomarkers or genomics for diagnosis or prognosis. For transplantation and cellular therapy trials, and comparative trials of treatment regimens versus transplantation see 700s. For health services or outcomes research see 902 or 905.

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

Basic and translational studies of multiple myeloma, MGUS, amyloidosis and other plasma cell dyscrasias. Includes interactions of myeloma cells with the microenvironment, such as bone, and with the immune system, and use of pre-clinical models to investigate pathophysiology and therapies. Basic mechanistic investigations of neoplastic transformation at a genetic/epigenetic/gene expression/metabolic or signal transduction level may be better suited to 603, and pharmacologic development of new therapeutic agents to 605.

652. Multiple Myeloma: Clinical and Epidemiological

Clinical retrospective/observational or epidemiological studies of risk factors, diagnosis, complications, treatment of complications, prognosis, quality-of-life, and analysis of diagnostic or prognostic biomarkers including “omics” in multiple myeloma. For clinical and epidemiological studies in MGUS, amyloidosis, or other non-myeloma plasma cell dyscrasias see 654. For health services or outcomes research see 902 or 905.

653. Multiple Myeloma: Prospective Therapeutic Trials

Prospective clinical trials of tumor-directed chemotherapy or other drugs, biological agents, non-cellular immunotherapies, vaccines, and other treatments for multiple myeloma. For prospective clinical trials in MGUS, amyloidosis, or other non-myeloma plasma cell dyscrasias see 654. For transplantation and cellular immunotherapies, and comparative trials of treatment regimens versus transplantation or cellular immunotherapies, see 700s. For health services or outcomes research, see 902 or 905.

654: MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological (NEW FOR 2023)

Clinical and epidemiological studies of risk factors, diagnosis, complications, treatment (prospective or observational), prognosis, quality-of-life, and analysis of diagnostic or prognostic biomarkers including “omics” in MGUS, amyloidosis, and other plasma cell dyscrasias (not including multiple myeloma). For multiple myeloma clinical and epidemiological studies see 652 and 653. For health services or outcomes research, see 902 or 905.

700s - Transplantation and Adoptive Cell Therapies

701. Experimental Transplantation: Basic and Translational

Preclinical investigations of topics relevant to HSPC transplantation, including conditioning, HSPC mobilization, engraftment, rejection, transplant complications, disease activity, immune function and reconstitution, GVHD, and graft-versus-tumor effects.

703. Cellular Immunotherapies: Basic and Translational

Preclinical development of cellular immunotherapies, excluding HSPC transplantation, and including T cells, NK cells, regulatory cells, dendritic cells, and other cell populations designed to treat malignancies or other hematologic diseases. This category also includes preclinical development of genetically engineered immune cells such as those expressing chimeric antigen receptors or engineered T cell receptors. Pre-clinical and mechanistic studies of the toxicities of these therapies are appropriate. Clinical studies see 704 or 705, and pre-clinical scale-up, collection or manufacturing studies see 711.

704. Cellular Immunotherapies: Early Phase and Investigational Therapies

Early phase (1 or 2) clinical studies of cellular immunotherapies. Encompasses unmanipulated, expanded, or genetically engineered immune cells (eg expressing chimeric antigen receptors, engineered T cell receptors, or other introduced molecules) administered to patients with malignancies and other hematologic or infectious diseases. Includes the diagnosis and treatment of toxicities. For preclinical development of cellular immunotherapies see 703. For late phase (3 or 4) clinical trials and studies of commercially available cellular therapies see 705. Health services or outcomes research see 900s.

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies

Late phase (3 or 4) clinical trials and studies of commercially available cellular immunotherapies, including comparisons to non-cellular therapies in specific diseases. Encompasses unmanipulated, expanded, or genetically engineered immune cells (eg expressing chimeric antigen receptors, engineered T cell receptors, or other introduced molecules) administered to patients with malignancies and other hematologic or infectious diseases. Includes the diagnosis and treatment of toxicities. For preclinical development of immunotherapies see 703. For early phase clinical studies see 704. Health services or outcomes research see 900s.

711. Cell Collection and Processing

Development and manufacturing of hematopoietic stem and progenitor cell (HSPC) grafts and adoptive cell therapies, including cellular and engineered immunotherapies. Encompasses clinical mobilization of HSPCs, collection of cells (including leukapheresis, marrow harvest or cord blood procurement), purification, cryopreservation, purification or purging, expansion, and modification of stem cells or immune cells, or any other cell collection or cell processing topics not fitting in 401. Experimental studies or clinical development of mesenchymal or other stromal cell populations see 506. Basic and translational studies of HSPC mobilization, engraftment or expansion see 701. Health services or outcomes research see 900s.

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities

Clinical and epidemiological allogeneic transplantation studies encompassing engraftment, rejection and chimerism, conditioning regimens, acute toxicities other than GVHD, infectious complications and prophylaxis, and supportive care such as transfusions and cytokines. Health services or outcomes research see 900s.

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution

Clinical and epidemiological studies covering risk factors, biomarkers, detection, prevention, and management related to acute and chronic graft-versus-host disease (GVHD) and to immune reconstitution and vaccine responses following allogeneic transplantation. Health services or outcomes research see 900s.

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence

Clinical and epidemiological studies focusing on late effects and on treatment of disease recurrence following allogeneic HSPC transplantation, including fertility, growth and development, lymphoproliferative syndromes, quality-of-life or secondary malignancies. Includes studies focusing on risk factors, prevention, detection and treatment of relapse and other late complications. Immune reconstitution and vaccination responses see 722. Health services or outcomes research see 900s.

731. Autologous Transplantation: Clinical and Epidemiological

Clinical and epidemiological studies focusing on disease response, complications, relapse, survival, and late effects of autologous transplantation. Includes disease-specific outcomes and trials comparing autologous transplantation to other therapies. Health services or outcomes research see 900s.

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

Clinical and epidemiological studies focusing on disease activity and survival following allogeneic transplantation, including risk factors and biomarkers for outcomes. Includes trials comparing allogeneic transplantation to other non-transplantation therapies in specific diseases. Excludes studies on specific acute and late toxicities (see 721-723). Health services or outcomes research see 900s.

800s - Gene Therapies, Chemical Biology, and Emerging Diagnostics

801. Gene Therapies

Basic, translational, and clinical studies of gene therapies, including gene addition, gene editing, and other approaches targeting genes, as applied to benign and malignant blood diseases. Studies focused specifically on the pre-clinical or clinical development of genetically engineered immune cells (ie CAR-T cells) see 703-705. Health services or outcomes research see 900s.

802. Chemical Biology and Experimental Therapeutics

Application of small molecule design and discovery to understanding and treating blood diseases. This category includes chemical probe discovery, chemical optimization of molecules as therapeutic agents, and comparative analyses of pharmacologic agents in preclinical models. Applications and discovery via proteomics, combinatorial chemistry, target identification and validation, novel screening methodologies, high-throughput assay development, hit-to-lead methodologies, and lead optimization techniques are also appropriate for this category.

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology

The development and testing of new tools, algorithms, and methodologies to improve diagnostics and tailor therapeutics for blood diseases. It includes development of technologies designed for applications in routine clinical care as well as those more appropriate for a research setting. Technologies covered in this category might include new approaches or uses of genome sequencing, epigenomics, RNA-seq, digital PCR, minimum residual disease assays, “multiomics”, microbiome profiling, ex vivo drug sensitivity assays, target specific imaging (or other target-oriented technologies), bioinformatics, artificial intelligence or machine learning, imaging, and immunologic assay development. Application of these tools and assays once established belong in other categories. This category encompasses novel applications of machine learning and deep learning algorithms in both clinical and laboratory hematology.

900s - Health Services, Quality Improvement, and Outcomes Research

901. Health Services and Quality Improvement – Non-Malignant Conditions

Health services research on non-malignant hematologic conditions and their treatments, including transplantation or cellular therapies. Health services research aims to identify the most effective ways to organize, manage, finance, and/or deliver high quality care; reduce medical errors; and improve patient safety. Abstracts focused on the delivery of high quality care, quality-improvement studies, economics of hematologic services (cost-effectiveness analysis, cost-benefit/cost-utility analysis, resource utilization, epidemiology of cost and delivery of care), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), hematology education research (training programs, training and developing countries), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes should be submitted to 905. Abstracts on drugs or therapeutic trials will be better served in other categories.

902. Health Services and Quality Improvement – Lymphoid Malignancies

Health services research focused on lymphoid malignancies should be submitted to this category. Health services research aims to identify the most effective ways to organize, manage, finance, and deliver high quality care; reduce medical errors; and improve patient safety. Abstracts focused on the delivery of high quality care, quality-improvement studies, economics of hematologic services (cost-effectiveness analysis, cost-benefit/cost-utility analysis, resource utilization, epidemiology of cost and delivery of care), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), hematology education research (training programs, training and developing countries), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes should be submitted to category 904. Abstracts on drugs or therapeutic trials are not appropriate and will be better served in other lymphoid malignancy categories.

903. Health Services and Quality Improvement – Myeloid Malignancies

Health services research focused on myeloid malignancies should be submitted to this category. Health services research aims to identify the most effective ways to organize, manage, finance, and deliver high quality care; reduce medical errors; and improve patient safety. Abstracts focused on the delivery of high quality care, quality-improvement studies, economics of hematologic services (cost-effectiveness analysis, cost-benefit/cost-utility analysis, resource utilization, epidemiology of cost and delivery of care), decision analyses, clinical pathways and practice guidelines, patient preference studies, studies of decision aids or other patient tools, informatics (telemedicine, computer decision support), hematology education research (training programs, training and developing countries), and studies of innovative healthcare delivery models, including in developing countries, belong in this category. Abstracts on how health care services impact patient or population outcomes should be submitted to category 906. Abstracts on drugs or therapeutic trials are not appropriate and will be better served in other myeloid malignancy categories.

904. Outcomes Research – Non-Malignant Conditions

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category should focus on non-malignant hematologic disorders and include outcomes studies based on real world data sets including big data or registry studies, studies of patient-reported outcomes, real world studies of quality of life, symptom management or palliation, access to care, gaps between ideal and actual care, and studies of health outcomes in the developing world. Studies exploring how race, ethnicity, gender, age, and other factors influence healthcare outcomes also belong in this category. Quality improvement projects should be submitted to section 901. Abstracts reporting on therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this section and will be better served in other categories.

905. Outcomes Research –Lymphoid Malignancies

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category should focus on lymphoid malignancies and may include outcomes studies based on real world data sets including big data or registry studies, studies of patient-reported outcomes, real world studies of quality of life, symptom management or palliation, access to care, gaps between ideal and actual care, and studies of health outcomes in the developing world. Studies exploring how race, ethnicity, gender, age, and other factors influence healthcare outcomes also belong in this category. Quality improvement projects should be submitted to 902. Abstracts reporting on therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this section and will be better served in other categories.

906. Outcomes Research –Myeloid Malignancies

Outcomes research focuses on how health services impact health outcomes for individuals and populations. Abstracts appropriate for this category should focus on myeloid malignancies and may include outcomes studies based on real world data sets including big data or registry studies, studies of patient-reported outcomes, real world studies of quality of life, symptom management or palliation, access to care, gaps between ideal and actual care, and studies of health outcomes in the developing world. Studies exploring how race, ethnicity, gender, age, and other factors influence healthcare outcomes also belong in this category. Quality improvement projects should be submitted to 903. Abstracts reporting on therapeutic trials (including clinical trials with a quality-of-life endpoint) are not appropriate for this section and will be better served in other myeloid malignancy categories.